Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 21.7% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painopioidsubjectsdoublechronic
  Phrases that lowered it: breastpatientsmastectomytissuecorticosteroids
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 96 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 89.3% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 84464 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Use of Pecs Blocks in Combination With Exparel in Breast Reconstruction Surgery NCT05171179 · started 2021 · scored riskier than 53% of active trials completed
• Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction NCT02161705 · started 2014 · scored riskier than 57% of active trials terminated
• A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction NCT02044302 · started 2014 · scored riskier than 75% of active trials terminated
• Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion NCT03502395 · started 2017 · scored riskier than 8% of active trials completed
• Intraoperative Pectoral Block vs IV Analgesia for Pain After Modified Radical Mastectomy NCT07257874 · started 2025 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.